Marketresearchnews

Monday, 24 May 2021

Viral Vector Manufacturing Market Top Companies, Business Insights, Growth, Global Market Share, Global Market Size, Trends, Sales, Revenue, Forecast and Detailed Analysis 2027

Global Proteomics Market size is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 23.2 Billion in 2017 and is projected to grow at a CAGR of 14.1% over the forecast period. Proteomes are a set of proteins which are produced in a system, organism, or any biological entity. Study of proteomes is known as proteomics. It is used in various applications, like investigation of protein expression, transcriptional & post transcriptional studies, metabolic pathways, protein interaction in diseases, etc.

The factors such as increasing research & development activities in the healthcare industry, rising demand for personalized medicines, rising number of approvals of personalized medicines and increasing activities of drug discovery are expected to propel the growth of the market. According to Foley & Lardner LLP, Food and Drug Administration (FDA) approved 16 new personalized medicine therapies in 2017. However, the high cost of devices and lack of skilled researchers can hamper the market growth over the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6930

Segmentation:

The Global Proteomics Market has been segmented into equipment, service and applicationThe market, on the basis of equipment, has been segmented into chromatography, mass spectroscopy, protein microarray, x-ray crystallography, protein fractionation and others.The market, by services, has been segmented into laboratory services and data analysis & services. The laboratory services segment accounted for the largest market share owing to its benefits in effective diagnosis and research for drug discovery. Data analysis and services is expected to register the highest CAGR owing to increasing demand for data analytics.The market, by application, has been segmented into drug discovery, clinical diagnosis and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Proteomics Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European Proteomics Market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Proteomics Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Proteomics market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players:

GENERAL ELECTRIC COMPANY, Bio-Rad Laboratories, Inc., Danaher, Siemens Ltd., Thermo Fisher Scientific Inc. Inc., Agilent Technologies, Inc., Genzyme Corporation, Biognosys AG, Bruker, Luminex Corporation, Merck KGaA, PerkinElmer Inc., WATERS, Caprion Biosciences Inc. and others are some of the key players in the Global Proteomics Market.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global proteomics market owing to rising funding from government, rising awareness regarding applications of proteomics, cost effectiveness and increasing demand for personalized medicines. According to a report published in a journal named Leukemia Research in November 2017, personalized medicines improve life of cancer patients by 7 months at USD 32,000.

Europe is expected to hold the second largest position in the Global Proteomics Market. The market growth in this region is attributed to rising cancer research activities and government support. The proteomics market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and the Rest of the Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increasing demand for personalized medicine due to rising prevalence of cancer and other such diseases and presence of large number of manufacturers of personalized medicines in the region. According to a report published by the National Institute of Cancer Prevention and Research (NICPR), around 2.25 million people in India are living with cancer in 2018.

The Middle East & Africa are expected to hold the least share of the market. The market growth in this region is expected to be driven by a developing healthcare infrastructure.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/proteomics-market-6930

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Viral Vector Manufacturing Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

Global viral vector manufacturing market is expected to grow significantly over the forecast period. It is projected that the upcoming global viral vector manufacturing market trends expected to register a CAGR Approx. 22.65% with an expected market value of USD 319 million during the forecast period of 2018–2023. Gene therapy is one of the preferred treatment options for most chronic diseases, involving insertion of a functional copy of a gene into a defective cell. Viral vector methods are used in effective transfer of therapeutic gene into the target cells. Viral vectors used in gene therapy include retroviral vectors, adenoviral vectors and adeno-associated viral vectors.

Numerous factors such as rise in number of clinical trials, increase in the number of gene therapy candidates, and growing necessity for an effective mode of disease treatment are expected to drive the growth of the market. Also, the characteristics of viral vectors such as ability to express therapeutic genes efficiently, and non-pathogenic nature fuels the growth of the market. Moreover, several companies involved in the development of viral agent-based products often seek support in terms of strategic collaborations and acquisitions with contract service providers to deliver a clinical grade product. This is mainly because of the limited availability and complexity of platform and technologies used for vector designing, production, packaging, and release testing. For example, in December 2017, Merck announced a commercial supply agreement to manufacture viral vectors for Bluebird Bio, Inc. for its use in potentially transformative gene therapies. This move will accentuate the life science business of Merck as a leading contract manufacturing organization and commercial provider of viral vectors for gene therapy.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6890

However, high cost of gene therapies and possible mutagenesis may hamper the market growth during the assessment period.

Segmentation:

The global viral vector manufacturing market has been segmented into type, disease, application, and end-user.

The market, on the basis of type, has been segmented retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors.

The segment, by retroviral vectors is anticipated to be the largest segment. Retro viruses contain an enzyme reverse transcriptase which allows the integration into the host genome. This has increased the usage of retroviral vectors in various treatment options, whereas the adenoviral vectors segment is estimated to be the fastest growing segment owing to their increased use in the in-vivo and in-vitro experiments.

The market, by retroviral vectors, has been further segmented into lentiviral vectors and gamma-retroviral vectors.

The market, by disease, has been segmented into cancer, genetic disorders, infectious diseases, and others.

The market, by application, has been segmented into gene therapy and vaccinology.

The market, by end-user, has been segmented into pharmaceutical and biotechnology companies, research institutes, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The viral vector manufacturing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European viral vector manufacturing market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The viral vector manufacturing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The viral vector manufacturing market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players:

FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., and Kaneka Eurogentec S.A. are some of the key players in the global viral vector manufacturing market.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global viral vector manufacturing market owing to a well-developed healthcare sector and rising prevalence of autoimmune and chronic diseases. According to a study published by Partnership to Fight Chronic Disease (PFCD) in 2016, 191 million people in America had at least 1 chronic disease, whereas 75 million had 2 or more chronic diseases in the year 2015.

Europe is expected to hold the second largest position in the global viral vector manufacturing market. The market growth in this region is attributed to the availability of funds for research and increasing healthcare expenditure. According to the European Commission, in 2016 the total expenditure of the governments of the European Union on health amounted to 7.1% of GDP. Also, according to National Institute of Health Funding (NIHR) in the year 2016, a funding of Euro 928 million was announced for new NIHR Biomedical Research Centres (BRC) and NIHR Clinical Research Facilities (CRF) for 5 years starting from April 2017.

Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.

On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to the growing government initiatives for the healthcare sector.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/viral-vector-manufacturing-market-6890

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Research report covers the Orphan diseases Market share and Growth, 2020-2027

Market Scenario:

Global orphan diseases market also known as rare disease is growing rapidly. It affects a very small percentage of the global population. Most of the orphan diseases are genetic and is remains throughout the life of the patient. There are no exact number of diseases available but approximately there are about 7000 different rare diseases and disorders throughout the globe. Global orphan diseases market is expected to grow at the average CAGR of 24.9% constantly throughout this period 2015-2022. It is also expected that this market which was US$ 121.6 billion in 2015 will grow to US$ 576.9 billion by 2022.However due to lack of awareness, correct diagnosis, correct treatments and availability of healthcare facilities are inhibiting the growth of the global orphan diseases market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2547

Segments:

Global orphan diseases market has been segmented on the basis of types of diseases which includes autoimmune disorders, genetic disorders, blood disorders, cancer, growth disorder, cardiovascular diseases, neurological disorders, respiratory disorders, digestive disorders, eye disorders and others. On the basis of treatment type it segmented into gene therapy, cell therapy, drug therapy and others. On the basis of end user the market is segmented into hospital and clinics, research laboratory and others.

Regional Analysis of Global Orphan diseases Market:

Considering the global scenario of this market, North American region is believed to have the largest orphan diseases market share. Moreover the European market is also growing and is the second largest market for global orphan diseases. On the other hand, Asia-Pacific’s orphan disease market is expected to grow at a significant rate during the forecasted period. Rest of the World is likely to have a limited but steady growth with respect to this market.

Key Players for Global Orphan diseases Market:

Some of the key players in this market are: Bristol-Myers Squibb Company (US), Novartis AG (Switzerland), CELGENE CORPORATION (US), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Alexion (US), Sanofi (French), Vertex Pharmaceuticals Incorporated (US), GlaxoSmithKline plc. (UK), Merck & Co., Inc (US), AbbVie Inc. (US)

The report of global orphan diseases market by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts and key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of different markets segments and regions.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/orphan-diseases-market-2547

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Vitiligo Treatment Market Is Seeing Explosive Growth by Future Industry Winners: Forecast, 2020-2027

According to MRFR analysis, Vitiligo Treatment Industry is expected to register a CAGR of 5.6% during the forecast period of 2019 to 2025 and was valued at USD 1.22 Billion in 2018.

Vitiligo is a skin disorder that causes white patches to appear on the skin. These patches occur because the melanocytes are destroyed, leaving areas of skin with no pigment at all. It can affect any skin part of the body.

The growth of the global vitiligo treatment market is driven by various factors such as emerging therapies for skin disorders, increasing healthcare expenditure, lifestyle changes. However, the lack of skilled professionals is expected to curb the growth of the global vitiligo treatment market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8442

Several market players currently dominate the global vitiligo treatment market. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, Incyte Corporation reported positive results from the study of ruxolitinib cream which is in phase 2. This topical cream is suggested for vitiligo treatment.

Segmentation

The global vitiligo treatment market has been segmented based on type, treatment type, and end-user.

The market, based on type, has been divided into non-segmental and segmental. On the basis of treatment type, the market has been segmented into therapy, surgery, medication, and others. The therapy is further segmented into light therapy and depigmentation. The surgery is segmented into skin grafting, blister grafting, and micro-pigmentation. The medication is segmented into topical corticosteroids and immunosuppressive drugs.

The end-user segments of the market consist of hospitals, aesthetic clinics, and others. The hospitals and clinics segment is expected to hold the largest share of the market as these centers are the primary locations for patients receiving treatment and surgery.

Key Players

Some of the Key Players in the Global Vitiligo Treatment Market are Bausch Health Companies Inc. (Laval, Quebec), STRATA Skin Sciences (Horsham, PA), Reddy’s Laboratories Ltd. (India), Allergan, Inc. (Dublin, Coolock), Clinuvel Pharmaceuticals Limited (Melbourne, Victoria), Astellas Pharma Inc. (Northbrook, IL), Novartis AG (Basel, Basel-Stadt), Eli Lilly Company (Indianapolis, Indiana), Incyte Corporation (Wilmington, Delaware), AstraZeneca AB (Cambridge, Cambridgeshire), Epizyme, Inc. (Cambridge, MA), Pfizer Inc. (New York),and Baxter International Inc. (Deerfield, Illinois)

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is expected to be the largest market owing to the significant investments by healthcare and medical regulatory bodies in vitiligo treatment to deliver quick medical aid to patients. The vitiligo treatment market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European vitiligo treatment market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The vitiligo treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing number of patients with vitiligo and increasing mergers & acquisitions among the market players are boosting the Asia-Pacific region. The vitiligo treatment market in the Middle East & Africa has been divided into the Middle East and Africa.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/vitiligo-treatment-market-8442

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

New research report offers detailed research on developments in Gene Therapy Market 2027

According to MRFR analysis, the global gene therapy market report expected to register a CAGR of 40.7% during the forecast period of 2019 to 2025 and was valued at USD 524 million in 2018.

Gene therapy is a technique in which a piece of DNA is incorporated into the cell via a vector. The key players are investing in the manufacturing of cell and gene therapy treatments due to its target specificity. The gene therapy is mainly of two types, somatic gene therapy, and germline gene therapy, depending on the type of cells its targets.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8399

The growth of the global gene therapy market is attributed to various factors such as robust product pipeline, increasing investment by key players, and high prevalence of target diseases and demand for innovative medication. However, the high cost of product development and stringent regulatory policies are expected to curb the growth of the global gene therapy market. The global gene therapy market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increasing prevalence of gene therapy and rising per capita healthcare expenditure. The gene therapy market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European gene therapy market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The gene therapy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing number of patients and raising awareness about the treatment methods, the market in Asia-Pacific is expected to be the fastest-growing. The gene therapy market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The global gene therapy market has been segmented based on product, indication, and end user.

The market, based on product, has been divided into kymriah, luxturna, yescarta, zolgensma, strimvelis, zynteglo, imlygic, and others.

The global gene therapy market has on the basis of indication is segmented, into oncology, genetic diseases/ disorders, and others. The oncology segment is expected to hold the largest market share and to be the fastest-growing segment due to high prevalence of cancer and robust pipeline for cancer gene therapy.

The end-user segments of the market are hospitals & clinics, specialty treatment centers, and others. The hospitals & clinics segment is expected to hold the largest market share due to increasing number of hospitals. Also, hospitals are generally the first treatment choice for diseases.

Key Players

Some of the key players in the global gene therapy market are Amgen, Inc. (US), Novartis AG (Switzerland), Spark Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), uniQure N.V. (Netherlands), Orchard Therapeutics plc (UK), Celgene Corporation (US), Bristol-Myers Squibb Company (US), Thermo Fisher Scientific Inc. (US), CEVEC (Germany), and Lonza (Switzerland).

Saturday, 22 May 2021

Research report covers the Nerve Stimulators Market Forecasts and Growth, 2020-2027

The Global Nerve Stimulators Market is expected to register a CAGR of 9.7% to reach USD 10,978.5 million till 2023. Nerve stimulation is a therapy that uses low-voltage electrical current for pain relief. The nerve stimulator used in nerve stimulation therapy is a bit like a heart pacemaker. In peripheral nerve and spinal cord stimulation, small pulse generator delivers electrical pulses to the nerves or the spinal cord. Nerve stimulator therapy has also proved as an efficient approach to get relief from neurological disorders. Among neurological disorders, nerve stimulation therapy is most commonly used for epilepsy and depression.

Rising incidence of chronic health problems, technological improvements, increasing geriatric population, and improved reimbursement policies in developed countries are expected to enhance the market growth. However, the lack of skilled or trained physicians and high cost of nerve stimulation therapy are projected to curb the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5258

Market Dynamics

Nerve stimulators have been gaining significance in recent years, owing to the increasing incidence of chronic health problems and increasing geriatric population. For instance, according to a study published in Pain Research and Management in 2017, the prevalence of chronic pain among Brazilian population was 39%, 31.7% in the French population, 48% in the UK, and 50% in the UK. Moreover, According to WHO, it is estimated that the world’s population aged 60 years and older will nearly double from 12% to 22% by 2050.

Segmentation

The global nerve stimulators market, by type, has been segmented into deep brain stimulator, a vagus nerve stimulator, and spinal cord stimulator. Based on applications, the nerve stimulators market has been classified as chronic pain, depression, dystonia, epilepsy, Parkinson’s disease, and others. Based on end user, the market has been classified as ambulatory surgical centers, hospital & clinics, trauma centers, and others.

Regional Analysis

The global nerve stimulators market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is expected to hold the largest share of the global nerve stimulators market. North America is expected to dominate the market, mainly due to the increasing geriatric population. According to a study published in the Drug and Alcohol Dependence journal in 2017, more than 100 million adult Americans are living with chronic pain. Chronic low back pain and headaches are the most commonly diagnosed conditions. It is also stated that conditions are more prevalent in women than men, i.e., 34.3% in women, and 26.7% in men in the US.

Europe is expected to account for the second-largest market share during the forecast period. The factors responsible for market growth in this region are the presence of huge geriatric population and high healthcare spending.

Asia-Pacific is estimated to be the fastest-growing region in the global market due to the presence of a vast neurological disorder’s patient population, presence of tremendous opportunities for the development of the market drive the growth of the nerve stimulators market in Asia-Pacific. According to a study published in Neurology India journal in 2014, it is found that out of a total population of India, around 30 million people were suffering from neurological disorders in India.

The nerve stimulators market in the Middle East & Africa is expected to grow due to the presence of a well-developed healthcare sector.

Key Players

The prominent players in the global nerve stimulators market are Boston Scientific Corporation, Medtronic, Cochlear Ltd, St Jude Medical, Inc., Cyberonics, Inc., Aleva Neurotherapeutics SA, and NeuroPace, Inc.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/nerve-stimulator-market-5258

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Sterilization Technology Market to Witness Widespread Expansion During 2020-2027

Sterilization refers to a process that eliminates, or kills all pathogens using various technologies and methods that are applied for sterilization of equipment and medical devices in healthcare institutes. There is an increase in demand for sterilization technologies across the globe. Patient safety and the prevention of hospital-acquired infections being a significant concern have led to the rise in the demand for sterilization technologies in healthcare. The global sterilization technology market is expected to register a CAGR of 8.20% and is anticipated to reach USD 8,142.61 million by 2023.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1312

Market Dynamics

Sterilization is the process that destroys or eliminates all forms of microbial life and is carried out in health-care facilities by physical or chemical methods. Sterilization technology includes processes such as gamma radiation, electron beam radiation, filtration, ionizing radiation, and thermal sterilization methods to destroy all microorganisms on the surface of an article or in a fluid to prevent disease transmission.

The sterilization technology market is driven by the increasing occurrences of hospital-acquired infections, increasing number of surgical procedures, growth in the pharmaceutical and biotechnology industries, and rising technological advancements in sterilization equipment. However, the stringent regulatory framework is expected to hamper the growth of the market during the forecast period.

Hospital-acquired infections are healthcare-associated infections that occur in patients under medical care who are not present or incubating at the time of admission. According to the World Health Organization, hundreds of millions of patients are affected by healthcare-associated infections (HAI) worldwide each year, leading to significant mortality and financial losses for health systems. Further, as per the European Centre for Disease Prevention and Control, approximately 30% of patients in Intensive Care Units (ICUs) are affected by at least one episode of healthcare-associated infection. Additionally, according to the World Health Organization (WHO), the prevalence of healthcare-associated infections varies between 5.7% and 19.1% in low- and middle-income countries. These increasing occurrences of HAIs have been leading to substantial financial losses for the overall healthcare system. This vast population affected with HAI are due to insufficient applications of standard and isolation precautions, whereas disinfection and sterilization ensure that medical and surgical instruments do not transmit infectious pathogens to patients. This considerable population affected with HAI and inversely rising need for sterilization are paving the way for a growth curve in the sterilization technology market

Segmentation

The global sterilization technology market has been segmented into type of sterilization, process, and end-user.

The global sterilization technology market based on the type of sterilization has been segmented into ethylene oxide, ionizing radiation (gamma radiation, electron beam radiation, and X-ray radiation), filtration, thermal sterilization, and others. Ethylene oxide takes accounted for 48.1% of sterilization technology market share, due to its high penetration, the strength of the radiation dose, and its exposure time. However, ionizing radiation is also likely to take up equal share due to significant health concerns related to the use of ethylene oxide.

The global sterilization technology, by the process, has been segregated into the chemical process (hydrogen peroxide, ozone, and chlorine dioxide), physicochemical (plasma and steam), synergetic processes (psoralens & UVA and low-temperature steam & formaldehyde), and physical processes (microwaves and pulsed light system). These processes use different compounds for sterilization of articles or surfaces.

Based on the end user, the market has been divided into the pharmaceutical industry, hospitals & clinics, and medical device manufacturers. Pharmaceutical industry dominates the global market for sterilization technology. It accounted for the largest market share of 38.4% and was valued at USD 1948.10 million in the year 2017 and is expected to reach USD 3163.60 million by 2023. Effective sterilization processes are vital within the pharmaceutical industries, and the safety of process units and final products depends on the highest quality of hygienic practice, as well as strict controls and regulatory compliance.

Key Players

The prominent players in the global sterilization technology market are Advanced Sterilization Products Services Inc., Atec Pharmatechnik GmbH, Sterile Technologies Inc., Steris PLC, 3M Company, Feldmeier Equipment Co., Donaldson Co. Inc., and Beta Star Life Science Equipment Inc.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/sterilization-technologies-market-1312

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com